glp 1 and breast cancer Can GLP-1 Medications Reduce Risk? Glucagon-like peptide 1 receptor agonists
Description
Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Chin K, et al

Include statistics on the prevalence of compounded GLP-1s on platforms like Groupon to emphasize the scope of the issue
doi: 10.2337/dc12-2504
People with existing eye conditions, pancreatitis history, or those on multiple medications should be cautious

Despite the demonstrable importance of surveillance of lean mass during testing of obesity drug candidates, it is common for only fat mass loss or total body weight loss to be measured or presented in pre-clinical and early clinical trials

Emerging Role of Dual GLP-1 Receptor Agonists
